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Abstract
Background: Randomised controlled clinical (drug) trials supply high quality evidence for therapeutic strategies in
primary care. Until now, experience with drug trials in German general practice has been sparse. In 2007/2008, the
authors conducted an investigator-initiated, non-commercial, double-blind, randomised controlled pilot trial (HWI-
01) to assess the clinical equivalence of ibuprofen and ciprofloxacin in the treatment of uncomplicated urinary tract
infection (UTI). Here, we report the feasibility of this trial in German general practices and the implementation of
Good Clinical Practice (GCP) standards as defined by the International Conference on Harmonisation (ICH) in mainly
inexperienced general practices.
Methods: This report is based on the experience of the HWI-01 study conducted in 29 German general practices.
Feasibility was defined by 1) successful practice recruitment, 2) sufficient patient recruitment, 3) complete and
accurate data collection and 4) appropriate protection of patient safety.
Results: The final practice recruitment rate was 18%. In these practices, 79 of 195 screened UTI patients were
enrolled. Recruitment differed strongly between practices (range 0-12, mean 2.8 patients per practice) and was
below the recruitment goal of approximately 100 patients. As anticipated, practice nurses became the key figures
in the screening und recruitment of patients. Clinical trial demands, in particular for completing symptom
questionnaires, documentation of source data and reporting of adverse events, did not agree well with GPs’
documentation habits and required support from study nurses. In many cases, GPs and practice staff seemed to be
overwhelmed by the amount of information and regulations. No sudden unexpected serious adverse reactions
(SUSARs) were observed during the trial.
Conclusions: To enable drug trials in general practice, it is necessary to adapt the setup of clinical research
infrastructure to the needs of GPs and their practice staff. Risk adaption of clinical trial regulations is necessary to
facilitate non-commercial comparative effectiveness trials in primary health care.
Trial Registration: Trial registration number: ISRCTN00470468.
Background
Randomised controlled clinical (drug) trials (RCTs) pro-
vide high-quality evidence for therapeutic decisions in
all fields of medicine. For primary care research, drug
RCTs, especially without commercial interests, are of
particular relevance for two reasons:
First, primary care health conditions and their treat-
ment should be investigated in their specific setting,
since evidence from specialised structures with selected
patients cannot necessarily be transferred without being
re-evaluated. Second, compared with drug studies in
specialised settings, research questions in primary
care usually address a different issue (e.g. “step-down-
therapies”, less invasive and expensive therapies, or
comparative effectiveness of established treatments) and
focus on general populations with low disease preva-
lence, and a symptom-oriented approach.
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performed in several European countries, especially in
UK and The Netherlands [1-4]. Recently, several rando-
mised controlled educational intervention studies have
been conducted in German general practice [5-7], but
drug trials remain scarce.
In 2007/2008, we conducted a non-commercial,
double-blind, randomised controlled trial (HWI-01),
which aimed to test the clinical equivalence of a three-
day treatment course of 3 × 400 mg ibuprofen com-
pared to 2 × 250 mg ciprofloxacin for uncomplicated
urinary tract infection [8]. Following a mandatory
requirement of the funding organisation (German Fed-
eral Ministry of Education and Research) to prove feasi-
bility of the study design, the investigation was
conducted as a pilot trial with limited sample size.
Further information about the trial is given in table 1.
Methods
Feasibility was to be studied first since the German
health care system lacks a central database of physicians
or medical patient data that could be used for identifica-
tion of participants or extraction of data. Correspond-
ingly, we defined feasibility according to 1) successful
practice recruitment including training and co-operation
throughout the trial,
2) sufficient patient recruitment and follow up,
3) complete and accurate data collection and
4) appropriate protection of patient safety according to
the ICH-GCP guidelines [9].
Additional aspects of feasibility - i.e. personal/time/
financial resources - will also be considered.
The term “study team” will be applied to members of
the University Departments’ research teams consisting of
two study nurses and two GP researchers (IG, JB). “Study
nurse” represents a member of the study team, whereas
“practice team” includes GPs and practice nurses.
The trial was supported by the Hannover Clinical
Trial Centre (HCTC, a local co-ordination centre for
clinical trials), which was involved in the preparation of
the study protocol, materials, monitoring and data
management.
Practice recruitment, training, support
To achieve the target number of 30 participating prac-
tices, a convenience sample of 169 GPs in and around
Hannover and Goettingen was invited by personal letters.
Most of these practices had either previously been
involved in research projects initiated by one of the two
academic departments of general practice, or were mem-
bers of their academic teaching networks. An academic
Table 1 Antibiotics vs. ibuprofen for the treatment of
uncomplicated urinary tract infection:A clinical trial in
general practices
Protocol
number
HWI-01
EudraCT
registration
2006-006398-26
Trial sites ￿ 19 general practices in and around Hannover
￿ 12 general practices in and around Göttingen
Time period 2007/2008
Trial design ￿ Double blind, multicentre, randomised controlled
clinical equivalence trial, investigator initiated
Objectives ￿ To describe a first trend concerning the equivalence
of ibuprofen and ciprofloxacin in the treatment of
uncomplicated urinary tract infection
￿ To optimize documents and procedures of a
double-blind, randomised-controlled trial in German
general practices
￿ To assess the number of treatment failures within
the ibuprofen group
Condition ￿ Acute uncomplicated urinary tract infection
Endpoints ￿ Symptom resolution on day 4/7, symptom relief on
day 4
￿ Treatment failure in the ibuprofen group
Number of
patients
￿ 79 patients were included
Inclusion
criteria
￿ Women aged ≥ 18 years, written informed consent
￿ Symptoms of urinary tract infection (dysuria,
frequency, urgency, possible low abdominal pain)
Exclusion
criteria
￿ Any signs indicating a complicated UTI (i.e. fever,
back pain)
￿ Any conditions that may lead to complicated
infections (i.e. pregnancy, diabetes, renal diseases,
urinary tract abnormalities or past urinary surgery,
urine catheterization, immunosuppressive therapy,
other serious diseases, cancer),
￿ Previous urinary tract infection within the last
two weeks,
￿ Current use of antibiotics or non-steroidal
anti-inflammatory drugs,
￿ History of gastrointestinal ulcers; epilepsy, allergies
or other
￿ contraindications for trial drugs,
￿ Inability to understand the trial information or to
give informed consent
Ethics approval ￿ Research Ethics Committee of the University of
Goettingen Medical Center (2007/06/13)
￿ Trial conduct according to ICH-GCP-guidelines and
the Declaration of Helsinki
Treatment
plan
￿ First arm: ibuprofen 3 × 400 mg/3 days
￿ Second arm: ciprofloxacin 2 × 250 mg, 1 × placebo/
3 days
Funding ￿ German Federal Ministry of Research and
Technology (BMBF)
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Page 2 of 8GP researcher and a study nurse visited interested prac-
tices (pre-study-visit) to establish confidence and facili-
tate further co-operation. GPs and their practice teams
were informed about the trial and its special require-
ments, such as GCP-guidelines, data collection, moni-
toring etc. An incentive of 100 € per completely
documented patient was offered. The six-month patient
recruitment period started with an initiation visit, per-
formed by a staff member of HCTC in co-operation with
the study team (GP researcher and study nurse). This
visit provided practices with detailed instructions regard-
ing study procedures and handouts of all trial related
documents, tests and blinded trial medication. In particu-
lar, documentation within the case report form (CRF),
reporting source data and adverse events and the proce-
dure for deblinding in case of emergency were explained.
Additionally, practice teams were urged to call the study
team when they had any questions or problems concern-
ing the RCT. During the recruitment period, regular vis-
its to the practices by both an independent HCTC
monitor and one of the research team’ss t u d yn u r s e s
assessed the complete documentation with source data
for each included patient. In addition, these visits were
used to recapitulate trial workflow and documentation
requirements. Paper CRFs were used instead of electronic
CRFs as electronic documentation equipment within
German practices is variable [10].
Patient recruitment and follow up (see figure 1)
The aim was to include at least 100 patients in the trial.
Participating practices were requested to screen and
document all adult female patients presenting with typi-
cal UTI-symptoms during a six month period. As
German UTI patients usually consult their GP without a
prior appointment or on very short notice, crucial study
procedures as screening, enrolment and treatment had
to be managed by practice teams without on-site sup-
port from the study team. Thus, every effort was made
to prepare trial procedures compatible with practice
routines as far as possible. A trial workflow and a check-
list were provided to support the practice teams during
the screening and enrolment procedures.
According to the workflow instructions, as practice
nurses represented the first contact they were to inform
patients about the study. Nevertheless, practices were
allowed to modify this if it did not fit with their specific
working routines. Practice teams were instructed to
hand out trial information and symptom questionnaires
to all eligible patients, including those who chose not to
participate, so that we could assess the denominator for
recruitment. Follow-up was to be conducted by the
study nurses who performed structured telephone inter-
views on day 4, 7 and 28.
Correct/complete data
CRF documentation at inclusion involved information
on in- and exclusion criteria, a patient’s history, basic
clinical information including diagnoses and medica-
tion as well as pregnancy test and dipstick results.
Completed symptom questionnaires and informed con-
sent sheets had to be obtained and filed. During the
follow-up period, urine culture results and information
about potential adverse events (AEs) were to be docu-
mented in the CRF. In addition, all further patient-
related information such as clinical findings or obser-
vations necessary for the evaluation of the trial (source
data) had to be documented in patients’ records. The
practice team was informed of the importance of data
quality, and notified of data review during the subse-
quent monitoring visits. Both the study protocol and
patient information materials were developed with
the support of HCTC to ensure compliance with
regulatory requirements.
Safety aspects
During trial participation all adverse events (AEs) were
recorded, including conditions or symptoms where asso-
ciation with study medication seemed highly unlikely.
Should AEs lead to a consultation, this had to be docu-
mented by the GPs; otherwise they were documented by
the study nurses during follow-up telephone interviews.
Approval by ethics committees (University of Goettin-
gen and Hannover Medical School) and the German
Institute for Pharmaceuticals and Medicine products
(BfArM,) was obtained before starting the trial.
Results
Recruitment and cooperation with practices
O fa l l1 6 9i n v i t e dG P s ,3 5e x p r e s s e da ni n t e r e s ti nt h e
study and 29 (23 male, 6 female) finally agreed to parti-
cipate. Main reasons for non-participation were lack of
time or personal resources as well as ethical reservations
regarding UTI management without antibiotics. A total
of 28 GPs completed the six months recruitment period.
One GP withdrew for ethical reasons citing non-
antibiotic UTI management before patients were
enrolled. With one exception, the GPs had no experi-
ence with drug trials according to GCP.
Both the pre-study visits and initiation visits informed
the practice team of study details and helped establish a
working relationship with the study team. However,
although GPs and practice staff showed an interest in the
study in general, many of them seemed to be over-
whelmed by the amount of information and regulations,
as clinical trial procedures differ significantly from obser-
vational or educational intervention studies. In particular,
GPs were astonished by the procedural complexity
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Page 3 of 8associated with both the documentation and reporting of
AEs and of source data (as required by German law).
During a total of 52 monitoring visits (1-3 per prac-
tice, duration 2-4 h), lists of errors and missing data
entries were presented to the GP, which had to be cor-
rected. Some GPs seemed to be glad that errors had
been detected and corrected; others resented “being
controlled”. Since an independent monitor had to be
involved trial costs for initiation and monitoring were
on average 600 € per monitoring visit. Concerning study
procedures, practice teams commented repeatedly that
they felt well supported by the workflow instructions
Figure 1 Trial workflow. Screening and enrolment procedures at inclusion Inclusion criteria: women with typical symptoms of UTI (dysuria and/
or frequency). Exclusion criteria: any signs indicating a complicated UTI (i.e. fever, back pain), any conditions that may lead to complicated
infections (i.e. pregnancy, diabetes, renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, immunosuppressive
therapy, other serious diseases, cancer), current use of antibiotics or non-steroidal anti-inflammatory drugs; history of gastrointestinal ulcers;
epilepsy, allergies or other contraindications for trial drugs; inability to understand the trial information or to give informed consent.
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procedures during their everyday routine.
In conclusion, recruitment of and co-operation with
practices for this drug trial were successful. However,
both GPs and academic study teams had to invest con-
siderable resources in terms of personnel and time for
training and supervision.
Patient recruitment
Patient recruitment and follow-up: A total of 195 UTI
patients were documented as having been screened, 65
had exclusion criteria and 50 refused to participate.
Excluding one screening failure, 79 patients were finally
enrolled - less than our target sample size of 100
patients. Recruitment differed strongly between prac-
tices (range 0-12); 3/29 practices had no study partici-
pants, 9/29 recruited only one patient whereas only two
practices enrolled 10 or more patients. The average
recruitment rate was 2.8 patients per practice. None of
the patients cancelled study participation during either
treatment or follow up. GPs who did not recruit
patients within a period of eight weeks were contacted
a n do f f e r e df u r t h e rt r a i n i ng. The most frequently
reported reasons for poor recruitment given during
phone calls were: no eligible cases, busy times in the
practice or practice vacation. Many GPs had overesti-
mated their potential for patient recruitment and as
anticipated, practice nurses became the key figure in
screening und recruitment of patients; they were usually
the first contact person. However, the additional time
required for screening and enrolment within a normal
consultation routine proved a considerable obstacle to
patient recruitment - most practice nurses and general
practitioners admitted that they had forgotten trial
screening in busy times. Thus, it is not possible to reli-
ably state the number of eligible patients. Further feasi-
bility issues in terms of trial requirements and related
problems are reported in table 2.
Data collection
On day 0, 72 of 79 symptom questionnaires had been
completed properly and were available for analysis. In
seven cases, practice teams had forgotten to collect
symptom questionnaires. In many practices, data had to
be completed with support from the study nurses. CRF
documentation during follow up (e.g. AEs and urine cul-
ture laboratory results) in particular was sometimes sim-
ply forgotten and had to be collated later.
As for symptom course, follow-up-data from tele-
phone interviews were available in 77 (day 4), 76
(day 7), 76 (day 28) of 79 cases, respectively. The omis-
sions arose as some patients could not be contacted by
phone. Source data documentation in patients’ records
was often inadequate but this could be resolved by
providing an extra source data sheet to capture the
extra information.
Safety
A total of 58 AEs were retrieved during the telephone
interviews, which were mainly described as slight dis-
comfort and did not necessarily lead to a further consul-
tation with the GP. The most commonly reported
symptoms were nausea, vomiting and diarrhoea (15/58),
followed by upper respiratory complaints (11/58). GPs
documented 23 AEs in the CRFs, which represented all
the adverse reactions that led to a GP consultation dur-
ing the 28 days of the study participation. Altogether,
the majority of the documented symptoms seemed to be
coincidental rather than directly related to the study
treatment. In two cases, serious AEs resulting in hospital
admissions were reported - one patient admitted herself
with abdominal pain during the trial participation (noth-
ing serious was found, and she was discharged after two
days); another was admitted with sudden hearing loss.
No sudden unexpected serious adverse reactions (SUS-
ARs) were observed during the trial.
Discussion
This double-blind randomised controlled drug trial in
German general practices proved feasible in terms of
both practice and patient recruitment, as well as with
respect to data quality and patient safety. However, due
to a lack of research training or familiarity with estab-
lished procedures (i.e. in documentation) and little pre-
vious experience of drug trials, the participating
practices required significant input from the academic
study team. Their willingness to invest extra time and
effort on behalf of the practices was essential to the suc-
cess of this study.
Barriers to performing an RCT in general practices
have been described before: Time constraints, elaborated
study procedures during routine consultations or a GP’s
lack of interest in the study theme can all hinder patient
recruitment [11-14]. In particular, studies requiring inci-
d e n tc a s e sa r ek n o w nt ob el e s ss u c c e s s f u l[ 1 5 ] .T h i si s
in line with our experience: patient recruitment during
regular consultation hours managed by the GP and
practice staff in the absence of on-site support by study
nurses represents a major challenge both for GPs and
the study team - and is likely to cause problems.
We additionally found that briefing GPs on GCP
basics within a short time (initiation visit) kept not only
the threshold for participation relatively low but also
created an additional problem as the information was
not sufficiently retained. The study team provided
phone support to ensure correct AE reporting. However,
during the trial regulations in Germany were tightened,
and now all investigators in clinical drug trials must
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itself, become a real obstacle as courses are time-
consuming and costly, and cur r e n t l yt a i l o r e dm o r et o
the needs of hospital-based investigators than GPs. It
remains unclear whether GPs can be expected to pay
for these out of their own pocket. In our experience, the
academic research team has an essential role in detailing
study requirements to the practice teams. As shown in
table 3, knowledge of practices’ working conditions and
close contact to the GP and his practice team are
important for a successful trial.
Quality management to ensure that correct procedures
and documentation are used through the trial requires
monitoring visits. These represent a considerable burden
for participating GPs and high costs for the trial.
Options for risk-adapted monitoring (ADAMON) as
described recently by Brosteanu et al. [16] should be
considered for non-commercial trials comparing the
effectiveness of established treatments and licensed
drugs.
Regulatory requirements: Though practice related pro-
cedures could be optimised by thorough preparation,
many regulatory demands seemed to be over the top
and have built up barriers rather than improved data
quality. Considering for example that the trial compared
two licensed, well-established treatments taken for
3 days, one of which is available over the counter,
demands on AE reporting were hard to justify to GPs.
As a result, many GPs did not implement procedures
such as prompt and detailed documentation reporting
any patient discomfort. This was also often the case for
source data documentation as it is unusual for a GP to
comment on conditions their patients do not have
(though this is mandatory in trials if the condition is an
exclusion criterion). GPs also reported that patients with
uncomplicated UTI found the legally required GCP
paperwork to give their consent to participate in the
t r i a lc o m p l i c a t e da n dt h a tm o s td i dn o ts e e mt or e a d
this carefully.
The problems related with extensive clinical trial regu-
lations have been discussed by many researchers in
conferences and working groups in recent years [17,18].
Table 2 Trial requirements and related problems
Investigator duties (GCP) Provided by the study team Problems encountered Possible causes
Knowledge of ICH-GCP guidelines and
regulatory requirements
￿ Information (ICH-GCP
guidelines, German drug law
etc.)
￿ Training units within
initiation/monitoring visits
￿ Further training units on
demand
￿ Written material was not
read
￿ Too much information provided in
initiation visits
Providing resources (time, staff) Clarify
responsibilities
￿ Workflow support
￿ Additional support on request
(by phone call, additional visits)
￿ Lack of personal resources
(during busy practice times)
￿ Under-estimation of additional trial
workload
￿ Recruitment of incident cases
Sufficient patient recruitment (screening,
enrolment and documentation of all UTI
patients)
￿ Involvement of practice nurse
￿ Support by instructions,
workflow
￿ Low recruitment in some
practices
￿ Incomplete documentation
for non-participants
￿ Time constraints
￿ Time gap between initiation visit and
first inclusion
￿ Number of refusals/patients with
exclusion criteria under-estimated
Comply with regulatory requirements with
respect to informed consent
￿ Extensive but GCP-conforming
information sheets
￿ Patients felt overwhelmed
with information
￿ Patients did not read
information completely before
signing
￿ Time-consuming procedure
￿ Information sheet too extensive
Ensure complete and correct documentation
(CRF, source data)
￿ Support by instructions,
workflow
￿ Data sheets for relevant
source data
￿ Incomplete CRFs
￿ Problems with report of AEs
￿ Extensive documentation not
compatible with existing
documentation habits
Abbreviations: CRF = case report form, ISF = investigator site file, AE = adverse event.
Table 3 Further implications for practice
Implications for practice
￿ Support recruitment: through close contact to GPs, reminders,
adequate reimbursement
￿ Keep trial procedures as simple and flexible as possible: checklists and
workflow instructions should be adapted to local practice habits
￿ Consider key roles: involve practice nurse in incentives and training to
optimise workflow
￿ Remember that time constraints are a major reason for insufficient
recruitment: make this a subject of discussion with the GPs and try to
find solutions
￿ Remember that the academic research team have an essential role in
detailing study requirements to the practice team, as well as practice
habits to external monitoring organisations
￿ Keep patient information as simple as possible
￿ Consider risk-adapted monitoring
￿ Prepare measures to optimise source data documentation (source data
sheets)
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aiming to insure maximum patient safety, also create a
maximum of documentation and bureaucracy. In case of
trials comparing licensed, commonly used drugs gener-
ally considered as safe, this may be excessive, and ham-
per trials rather than improve their quality [19-21]. As a
consequence, researchers demand a risk-adapted
approach of GCP-regulations and sensible guidelines to
simplify the conduct of trials when risk can be consid-
ered low [22,23]. Non-commercial comparative effective-
ness trials are particularly important both as a contrast
to commercial research interests and as a source of
urgently needed evidence for safe, effective and cost-
effective treatment options in primary care [24-26].
Strengths and Limitations: The main strength of this
paper refers to its “novice” setting in which feasibility,
barriers and facilitators of a clinical trial are reported by
combining study data, more narrative process data and
experience. On the other hand, this may also constitute
a limitation. This RCT was conducted as a pilot trial
with a relatively small sample size. Our experience can-
not be considered representative and should be inter-
preted with respect to this context and setting.
Conclusions
To enable drug trials in German general practice, it will
be necessary to adapt the setup of clinical research
infrastructure to the needs of GPs and their practice
staff. To support non commercial clinical comparative
effectiveness trials in primary health care, adaption of
clinical trial regulations to the risk engendered by the
trial seems necessary. For low risk trials using licensed
drugs, administrative procedures could probably be
reduced without compromising patient safety.
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